Immunex Enbrel Indication Upgrade To First-Line Requires More Safety Data
Executive Summary
The recommendation for second-line treatment of rheumatoid arthritis by Enbrel could be expanded to include first-line therapy if Immunex can provide data demonstrating long-term safety of the biologic therapy, FDA's Arthritis Advisory Committee agreed Sept. 16.